Publications
Mocravimod, a S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation
A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis
Received: January 15, 2020
Accepted: June 15, 2020
Published online: August 21, 2020
643 S1P/S1PR1 Signalis Required for Optimal T-Cell Pathogenicity to Induce Gvhd By RegulatingDrp1/mTOR Axis
Monday, December 13, 2021: 10:30 AM
S1P Receptor-1 agonist averts the De Novo Generation of Autoreactive T-cells in Murine Acute GVHD
Letter HemeSphere, powered by EHA (Aug-2021)
Short-term KRP203 and posttransplant cyclophosphamide for graft-versus-host disease prophylaxis
Bone Marrow Transplantation – Yokoyama, Teshima et al (2020)
Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists
Frontz Pharmacol
– Perez et al (March 2019)
ASBMT 2018: The Role of S1PR1 Agonism in Thymus-Dependent T-Cell Regeneration and Graft-vs.-Tumor Activity Following Experimental Allogeneic Hematopoietic Stem Cell Transplantation
Vollmer, Krenger (2018)
ASBMT 2018: The Role of S1PR1 Agonism in Thymus-Dependent Generation of Autoreactive T Cells during Experimental Acute Graft-vs.-Host Disease
Vollmer and Krenger (2018)
Sphingosine 1-Phosphate Signaling and Its Pharmacological Modulation in Allogeneic
Hematopoietic Stem Cell Transplantation, Smith & Gergely (September 2017)
S1P signaling: new therapies and opportunities F1000 Prime reports
Gonzales (December 2014)
Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD)
Patricia A. Taylor et al (2007)
GVHD prophylaxis with KRP203, a SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR, is safe and may have a potential to improve
Poster, Heim et al